# US 2021/0171667 A1 · Carboxyalkyl Chitosan

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171667 A1
- Document ID: US20210171667A1
- Status: Published application
- Kind: A1
- Application number: 16/767,571
- Filed: 2018-11-09
- Published: 2021-06-10
- Earliest claimed: 2017-11-28
- Assignees: KiOmed Pharma
- Applicants: KiOmed Pharma
- Inventors: Mickaël Chausson; Pierre Douette; Sandrine Emilia Gautier; Philippe Vaesen; Houtaï Choumane; Guillermo Rocasalbas
- Web page: https://patentgrep.com/patent/US20210171667A1

## CPC

- C08B 37/003: {Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof}
- A61K 8/736: {Chitin; Chitosan; Derivatives thereof}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/722: Chitin, chitosan
- A61L 27/20: Polysaccharides
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61Q 19/08: Anti-ageing preparations
- C08L 5/08: Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
- A61L 2400/06: Flowable or injectable implant compositions
- A61L 2430/06: for cartilage reconstruction, e.g. meniscus
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- C08L: COMPOSITIONS OF MACROMOLECULAR COMPOUNDS (compositions based on polymerisable monomers C08F, C08G; artificial filaments or fibres D01F; textile treating compositions D06)

## Abstract

The present invention relates to a carboxyalkyl chitosan, compositions comprising same, a process for manufacturing same, and various applications thereof, in particular in the field of therapy, rheumatology, ophthalmology, esthetic medicine, plastic surgery, internal surgely, dermatology or cosmetics.

## Claims

### Claim at position 1

1-16. (canceled)

### Claim 17

A carboxyalkyl chitosan of fungal origin, the carboxylkyl chitosan having glucosamine units, N-acetyl-glucosamine units, and glucosamine units substituted by a carboxyalkyl group, wherein the carboxyalkyl chitosan has a degree of substitution by the carboxyalkyl group that is greater than 20%, expressed as the number of moles of the substituent carboxyalkyl group relative to the number of moles of total units.

### Claim 18 (depends on 17)

The carboxyalkyl chitosan of claim 17, wherein the degree of substitution by a carboxyalkyl group is greater than 50%, expressed as the number of moles of the substituent carboxyalkyl group relative to the number of moles of total units.

### Claim 19 (depends on 17)

The carboxyalkyl chitosan of claim 17, wherein the degree of substitution by a carboxyalkyl group is less than 200%, expressed as the number of moles of the substituent carboxyalkyl group relative to the number of moles of total units.

### Claim 20 (depends on 17)

The carboxyalkyl chitosan of claim 17, wherein the chitosan is derived from the mycelium of a fungus of the type Ascomycetes and/or Basidiomycetes.

### Claim 21 (depends on 17)

The carboxyalkyl chitosan of claim 17, wherein the carboxyalkyl chitosan has a degree of acetylation ranging from 40% to 80%, expressed in number of moles of N-acetyl-glucosamine units relative to the number of moles of total units.

### Claim 22 (depends on 17)

The carboxyalkyl chitosan of claim 17, wherein the carboxyalkyl chitosan is reacetylated.

### Claim 23 (depends on 17)

The carboxyalkyl chitosan of claim 17, wherein the carboxyalkyl is sterilized.

### Claim 24 (depends on 17)

A composition comprising at least one of the carboxyalkyl chitosan of claim 17.

### Claim 25 (depends on 17)

An injectable composition comprising at least one of the carboxyalkyl chitosan of claim 17.

### Claim 26 (depends on 17)

A pharmaceutical composition comprising at least one of the carboxyalkyl chitosan of claim 17.

### Claim 27 (depends on 26)

The pharmaceutical composition of claim 26 selected from the group consisting of: an injectable pharmaceutical composition suitable for delivery via an injectable medical device, an implantable pharmaceutical composition suitable for delivery via an implantable medical device, and a pharmaceutical composition suitable for instillation via a instillation medical device.

### Claim 28 (depends on 26)

A therapeutic treatment method, the method comprising instilling, implanting, or injecting the pharmaceutical composition of claim 26 via a subcutaneous, intradermal, ocular, intraocular, or intra-articular route.

### Claim 29 (depends on 28)

The method according to claim 28, wherein the pharmaceutical composition is instilled, implanted, or injected in a body tissue selected from the group consisting of vocal cords, muscles, ligaments, tendons, cartilages, sexual organs, bones, joints, eyes, dermis, epidermis, the articular joints, and combinations thereof.

### Claim 30 (depends on 17)

A method for treating osteoarthritis or repairing a cartilage defect, the method comprising administering the carboxyalkyl chitosan of claim 17 to a subject in need thereof via injection into the synovial fluid, optionally after mixing with blood, or via implantation in the cartilage.

### Claim 31 (depends on 24)

A medical device comprising the composition of claim 24.

### Claim 32 (depends on 24)

A method of preparing the composition of claim 24, the method comprising:
dissolving the carboxyalkyl chitosan in an aqueous solution, optionally buffered, having a pH in a range of 6.2 to 8.5;
optionally adjusting the pH of the aqueous solution comprising the carboxyalkyl chitosan to a desired pH;
optionally adding a reducing sugar or other excipients;
optionally adjusting the osmolality of the aqueous solution comprising the carboxyalkyl chitosan and the optional reducing sugar or other excipients;
thereby forming the composition.
